- Home
- GILD vs ANET Comparison
GILD vs ANET Comparison
Compare GILD & ANET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- ANET
- Stock Information
- Founded
- GILD 1987
- ANET 2004
- Country
- GILD United States
- ANET United States
- Employees
- GILD N/A
- ANET N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- ANET Computer Communications Equipment
- Sector
- GILD Health Care
- ANET Telecommunications
- Exchange
- GILD Nasdaq
- ANET Nasdaq
- Market Cap
- GILD 131.5B
- ANET 117.3B
- IPO Year
- GILD 1992
- ANET 2014
- Fundamental
- Price
- GILD $104.54
- ANET $71.20
- Analyst Decision
- GILD Buy
- ANET Strong Buy
- Analyst Count
- GILD 27
- ANET 16
- Target Price
- GILD $105.32
- ANET $105.58
- AVG Volume (30 Days)
- GILD 10.4M
- ANET 12.8M
- Earning Date
- GILD 04-24-2025
- ANET 05-06-2025
- Dividend Yield
- GILD 3.02%
- ANET N/A
- EPS Growth
- GILD N/A
- ANET 35.15
- EPS
- GILD 0.38
- ANET 2.23
- Revenue
- GILD $28,754,000,000.00
- ANET $7,003,146,000.00
- Revenue This Year
- GILD $1.80
- ANET $21.35
- Revenue Next Year
- GILD $3.83
- ANET $17.83
- P/E Ratio
- GILD $275.11
- ANET $31.93
- Revenue Growth
- GILD 6.04
- ANET 19.50
- 52 Week Low
- GILD $62.07
- ANET $59.43
- 52 Week High
- GILD $119.96
- ANET $133.58
- Technical
- Relative Strength Index (RSI)
- GILD 43.51
- ANET 39.02
- Support Level
- GILD $97.32
- ANET $69.13
- Resistance Level
- GILD $107.18
- ANET $76.78
- Average True Range (ATR)
- GILD 3.94
- ANET 4.88
- MACD
- GILD -0.45
- ANET 0.57
- Stochastic Oscillator
- GILD 41.42
- ANET 54.04
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.